A nem szteroid gyulladásgátlók emésztórendszeri mellékhatásai fokozott kockázatú betegekben--a specifikus ciklooxigenázgátlók szerepe.

Translated title of the contribution: Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Non-steroidal anti-inflammatory drugs (NSAID) are the most widely used drugs in the world. Gastrointestinal (GI) side effects of NSAID have a significant economical impact (3-4% clinical GI event, and 1.5% serious/life threatening GI event/year). Selective cyclooxigenase-2 inhibitors (coxibs) are equally effective as non-selective NSAID with about 50% reduction of serious/life threatening GI events. Serious GI events are significantly less in high-risk patients (history of peptic ulcer disease, age over 65 years, treatment with anticoagulants), therefore the use of coxibs is cost-effective in these population. Most of patients with long-term NSAID therapy also require co-therapy with acid suppression or prostaglandin analogue, but coxibs may replace both. The treatment with coxibs in long-term NSAID users thus is cheaper then non-selective NSAID + co-therapy. Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue.

Original languageHungarian
Pages (from-to)1899-1905
Number of pages7
JournalOrvosi Hetilap
Volume142
Issue number35
Publication statusPublished - Sep 2 2001

Fingerprint

Cyclooxygenase Inhibitors
Anti-Inflammatory Agents
Pharmaceutical Preparations
Synthetic Prostaglandins
Therapeutics
Drug Therapy
Acids
Drug Users
Peptic Ulcer
Anticoagulants
Costs and Cost Analysis
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{922d4dc664154c26a36c74e5b4cb0890,
title = "A nem szteroid gyullad{\'a}sg{\'a}tl{\'o}k em{\'e}szt{\'o}rendszeri mell{\'e}khat{\'a}sai fokozott kock{\'a}zat{\'u} betegekben--a specifikus ciklooxigen{\'a}zg{\'a}tl{\'o}k szerepe.",
abstract = "Non-steroidal anti-inflammatory drugs (NSAID) are the most widely used drugs in the world. Gastrointestinal (GI) side effects of NSAID have a significant economical impact (3-4{\%} clinical GI event, and 1.5{\%} serious/life threatening GI event/year). Selective cyclooxigenase-2 inhibitors (coxibs) are equally effective as non-selective NSAID with about 50{\%} reduction of serious/life threatening GI events. Serious GI events are significantly less in high-risk patients (history of peptic ulcer disease, age over 65 years, treatment with anticoagulants), therefore the use of coxibs is cost-effective in these population. Most of patients with long-term NSAID therapy also require co-therapy with acid suppression or prostaglandin analogue, but coxibs may replace both. The treatment with coxibs in long-term NSAID users thus is cheaper then non-selective NSAID + co-therapy. Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue.",
author = "L. Pr{\'o}nai",
year = "2001",
month = "9",
day = "2",
language = "Hungarian",
volume = "142",
pages = "1899--1905",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "35",

}

TY - JOUR

T1 - A nem szteroid gyulladásgátlók emésztórendszeri mellékhatásai fokozott kockázatú betegekben--a specifikus ciklooxigenázgátlók szerepe.

AU - Prónai, L.

PY - 2001/9/2

Y1 - 2001/9/2

N2 - Non-steroidal anti-inflammatory drugs (NSAID) are the most widely used drugs in the world. Gastrointestinal (GI) side effects of NSAID have a significant economical impact (3-4% clinical GI event, and 1.5% serious/life threatening GI event/year). Selective cyclooxigenase-2 inhibitors (coxibs) are equally effective as non-selective NSAID with about 50% reduction of serious/life threatening GI events. Serious GI events are significantly less in high-risk patients (history of peptic ulcer disease, age over 65 years, treatment with anticoagulants), therefore the use of coxibs is cost-effective in these population. Most of patients with long-term NSAID therapy also require co-therapy with acid suppression or prostaglandin analogue, but coxibs may replace both. The treatment with coxibs in long-term NSAID users thus is cheaper then non-selective NSAID + co-therapy. Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue.

AB - Non-steroidal anti-inflammatory drugs (NSAID) are the most widely used drugs in the world. Gastrointestinal (GI) side effects of NSAID have a significant economical impact (3-4% clinical GI event, and 1.5% serious/life threatening GI event/year). Selective cyclooxigenase-2 inhibitors (coxibs) are equally effective as non-selective NSAID with about 50% reduction of serious/life threatening GI events. Serious GI events are significantly less in high-risk patients (history of peptic ulcer disease, age over 65 years, treatment with anticoagulants), therefore the use of coxibs is cost-effective in these population. Most of patients with long-term NSAID therapy also require co-therapy with acid suppression or prostaglandin analogue, but coxibs may replace both. The treatment with coxibs in long-term NSAID users thus is cheaper then non-selective NSAID + co-therapy. Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue.

UR - http://www.scopus.com/inward/record.url?scp=0035797790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035797790&partnerID=8YFLogxK

M3 - Article

C2 - 11601177

AN - SCOPUS:0035797790

VL - 142

SP - 1899

EP - 1905

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 35

ER -